Search

A new report discusses research on autoimmune hepatitis, a condition in which the immune system mistakenly attacks the liver. The study analyzed the efficacy and safety of infliximab, a drug used in the treatment of autoimmune diseases, in patients with autoimmune hepatitis. The researchers found that infliximab was effective in achieving complete biochemical response in a majority of patients, particularly those who had failed standard or alternative therapies. The study suggests that infliximab may be a safe and effective rescue therapy for autoimmune hepatitis. [Extracted from the article]

A recent study conducted at Riga East University Hospital in Latvia examined the clinical features, treatment challenges, and outcomes of patients with autoimmune hepatitis over a five-year period. Autoimmune hepatitis is an inflammatory liver disease of unknown cause that can lead to cirrhosis and liver failure. The study found that the diagnostic criteria for autoimmune hepatitis were generally consistent with accepted principles, but the duration of therapy did not always align with guidelines. The researchers emphasized the importance of individualized treatment regimens and balancing treatment goals with personal choices. [Extracted from the article]

A study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, explores the role of B and T cells in the development of autoimmune hepatitis (AIH). AIH is a severe liver disease characterized by hypergammaglobulinemia, the presence of autoantibodies, and interface hepatitis. The study found that B cells play an active role in liver damage by presenting autoantigens to T cells, while Treg impairment contributes to the progression of liver damage. The research also discusses potential immunotherapeutic strategies to limit inflammation and restore tolerance to liver autoantigens. [Extracted from the article]

A 53-year-old man developed autoimmune cholestatic hepatitis while being treated with nivolumab for metastatic renal cell carcinoma. He experienced symptoms such as jaundice, nausea, and vomiting. Laboratory tests showed elevated liver enzymes and bilirubin levels. MRI scans did not reveal any abnormalities in the biliary tract. The patient had no history of liver or autoimmune disease, and there was no evidence of hepatotoxic medication, herbal or alcohol use. A liver biopsy confirmed the diagnosis of nivolumab-induced autoimmune cholestatic hepatitis. The patient's nivolumab treatment was discontinued, and he was started on methylprednisolone, which successfully normalized his bilirubin levels after several weeks. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of prednisolone in treating autoimmune hepatitis in a 22-month-old girl. The girl initially presented with jaundice, fatigue, and abnormal aminotransferase levels, and was subsequently diagnosed with autoimmune hepatitis and autoimmune hypothyroidism. Despite receiving prednisolone treatment, she did not have a biochemical response after 6 weeks. Further investigations revealed incompletely treated autoimmune hepatitis and an autosomal dominant STAT1 gain-of-function defect. Treatment with baricitinib was eventually started, resulting in normalized aminotransferase levels. The girl continued on baricitinib and prednisolone, along with infection prophylaxis. [Extracted from the article]

This article presents five case reports of patients who experienced various adverse effects or lack of efficacy while being treated with belimumab, omalizumab, ustekinumab, or vedolizumab for autoimmune hepatitis, inflammatory bowel diseases, chronic urticaria, Sjogren syndrome, or ulcerative colitis. The patients developed recurrent soft tissue infections, fatigue, arthralgia, or lack of efficacy during their treatment. The article does not provide specific details about the dosages, routes, durations of the treatments, or outcomes. [Extracted from the article]

Researchers from An-Najah National University have published a case report on a rare neoplasm called post-transplantation primary central nervous system lymphoma (PT-PCNSL) that occurs in immunocompromised patients. The report describes the case of a 64-year-old woman who had received a liver transplant for autoimmune hepatitis and presented with neurological symptoms. Brain MRI revealed multiple ring-enhancing lesions, and a brain biopsy confirmed the diagnosis of PT-PCNSL. This is the first reported instance of isolated CNS lymphoma in a liver transplant recipient with autoimmune hepatitis, successfully treated with a rituximab-methotrexate regimen. The timely recognition of PT-PCNSL is crucial for appropriate management and improved outcomes. [Extracted from the article]

A study conducted by researchers at Cliniques Universitaires Saint-Luc in Brussels, Belgium, evaluated the effectiveness of a ten-antigen immunodot test in diagnosing autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). The study analyzed serum samples from 111 patients and found that the immunodot panel accurately confirmed positive results from other diagnostic tests, except for two samples. The immunodot test also identified additional autoantibodies in samples initially negative by other tests. The researchers concluded that the immunodot technique is a quick, sensitive, and specific method that could improve diagnostic efficiency and accuracy in clinical practice for autoimmune liver diseases. [Extracted from the article]

A recent study conducted in Kerala, India, examined the etiology and epidemiological characteristics of alcoholic liver disease (ALD) in patients with compensated and decompensated cirrhosis at their first presentation to a hospital. The study found that decompensation was a rare presenting feature, indicating poor outcomes. Alcohol abuse was identified as the major risk factor for ALD, and patients with decompensated cirrhosis had higher Model for End-Stage Liver Disease (MELD) scores. The study highlights the importance of early detection and intervention for ALD. [Extracted from the article]

The patent application by inventor LAI, Laijun, filed on March 4, 2024, discusses methods for treating cancer and autoimmune diseases. It describes the use of antibodies that selectively bind to specific proteins to treat cancer, as well as the use of IgV domains from certain proteins or expression vectors to treat autoimmune disorders. The application provides detailed information on the amino acid sequences of the antibodies and their potential therapeutic applications. It also includes information on isolated antibodies, nucleic acids encoding these antibodies, fusion molecules, and pharmaceutical compositions for treating cancer and autoimmune disorders. [Extracted from the article]

A case report from Virginia Commonwealth University describes a successful simultaneous liver and kidney transplantation (SLKT) in a highly sensitized O recipient with organs from an A2 donor. The recipient was a 59-year-old woman with chronic kidney disease and liver failure. The study found that SLKT is feasible in patients with both donor-specific HLA antibodies and high anti-A2 titers. This research provides valuable insights into the field of transplant medicine and kidney transplants. [Extracted from the article]

A recent study conducted at the University of Michigan examined the clinical features, liver histology, and genetic variants associated with immune-mediated liver injury from checkpoint inhibitors (ILICI). The study analyzed 57 cases of ILICI and found that certain genetic variants involved in host T-cell regulation and drug disposition were associated with ILICI. The researchers concluded that these findings could potentially lead to improved diagnostic tools and treatments for ILICI. The study also noted that ILICI typically occurs within 12 weeks of initiating immunotherapy and is self-limited in most cases. [Extracted from the article]

A recent study conducted by researchers at the University of Medicine and Pharmacy in Iasi, Romania, explores the relationship between celiac disease (CeD) and liver damage. CeD is an autoimmune disorder that affects the gastrointestinal tract and can have extraintestinal symptoms. The study presents a case of severe liver damage in an obese 12-year-old boy, where CeD was diagnosed alongside autoimmune hepatitis. The researchers ruled out other potential causes of liver disease and concluded that the patient's obesity did not exclude the possibility of CeD. This research provides valuable insights into the overlap between celiac disease and liver damage. [Extracted from the article]

A report from the Children's Memorial Health Institute in Warsaw, Poland discusses the findings of a study on autoimmune hepatitis in pediatric patients. The study specifically focuses on classical autoimmune hepatitis and IgG4-associated autoimmune hepatitis. The researchers conducted a retrospective analysis of 23 children diagnosed with autoimmune hepatitis and compared them based on the presence of IgG4-positive plasma cells in liver biopsies. The study concludes that the presence of the IgG4 component is clinically insignificant and recommends the use of conventional immunosuppressive treatment for IgG4-associated autoimmune hepatitis. [Extracted from the article]

Researchers from Ghent University in Belgium have conducted a study to validate the International Autoimmune Hepatitis Group's (IAIHG) consensus criteria for treatment response in autoimmune hepatitis (AIH). The study involved a multicentric cohort of 200 AIH patients and found that achieving complete biochemical response (CBR) according to the IAIHG criteria was associated with superior liver-related and overall survival. The researchers concluded that the IAIHG criteria can be used as intermediate endpoints in future studies on non-corticosteroid treatments for AIH. This information is valuable for patients and healthcare professionals seeking to understand treatment response and improve outcomes in AIH. [Extracted from the article]

The article reports on the financial results of Kezar Life Sciences, Inc., a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, for the second quarter ended June 30, 2024. Topics discussed include comments from Chris Kirk, co-founder and chief executive officer (CEO) of Kezar and the partnership entered into by Kezar with Everest Medicines in September 2023.

A 44-year-old woman developed drug-induced autoimmune hepatitis while taking norethisterone for menorrhagia. She experienced symptoms such as lethargy, itching, and decreased appetite. The woman's liver enzymes were normal before starting the medication, and she was given treatment with n-acetyl cysteine. A diagnosis of drug-induced liver injury was suggested, and further tests confirmed norethisterone-induced autoimmune hepatitis. The woman's liver enzymes returned to normal after eight weeks of conservative management, and she had no relapse during one year of follow-up. [Extracted from the article]

A 50-year-old woman developed autoimmune-like hepatitis while being treated for borderline tuberculoid leprosy with rifampicin, dapsone, and clofazimine. She presented with red-colored raised lesions, itching, loss of sensation, and yellowish discoloration of the eyes. Further examination revealed liver enlargement, pancytopenia, and abnormal liver function tests. Rifampicin and dapsone were discontinued due to the possibility of drug-induced liver injury, and the patient was treated with prednisolone. Although she initially improved, her symptoms recurred after prednisolone was discontinued. The patient was ultimately diagnosed with drug-induced autoimmune-like hepatitis and unfortunately passed away due to sepsis-related complications. [Extracted from the article]

A 61-year-old woman developed autoimmune hepatitis while being treated with atorvastatin and alirocumab for familial hypercholesterolemia. After 4 days of taking atorvastatin, she experienced jaundice, nausea, epigastric pain, and soft yellow stool, and was diagnosed with acute hepatitis. Her treatment with atorvastatin was stopped, but her liver function tests remained abnormal, indicating autoimmune liver disease. She was later diagnosed with autoimmune hepatitis secondary to atorvastatin and was managed in the hospital. After discontinuing atorvastatin, her liver function improved, but when she started treatment with alirocumab, she developed jaundice and other symptoms. A liver biopsy confirmed autoimmune hepatitis secondary to alirocumab, and she was treated with prednisolone and azathioprine, which improved her liver function. She was also recommended treatment with colesevelam to control her lipid profile. [Extracted from the article]

A study conducted by researchers from Iwate Medical University in Morioka, Japan, highlights the case of a 37-year-old woman with severe acute liver injury caused by autoimmune hepatitis. Despite treatment with prednisolone, her prothrombin time (PT) did not return to normal levels. Further examination revealed that she had low factor VII activity, indicating a diagnosis of factor VII deficiency. The researchers suggest that altered coagulopathy should be considered in cases of liver injury with abnormal PT. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Warsaw in Poland has found that previous infection with the Hepatitis E virus (HEV) is associated with increased liver stiffness in patients with autoimmune hepatitis (AIH). AIH is a chronic liver disease that often requires lifelong immunosuppression. The study involved 374 adult patients with AIH, and it found that 15% of them were positive for anti-HEV antibodies. These patients had higher liver stiffness measurements, indicating more advanced liver fibrosis. However, the overall prevalence of anti-HEV antibodies in AIH patients was lower than in the general population of Polish blood donors. [Extracted from the article]

A recent study conducted at a Teaching Hospital has provided new insights into cutaneous lupus erythematosus, a condition where autoimmune hepatitis overlaps with subacute cutaneous lupus erythematosus. The study focused on a case of a 35-year-old male who had been diagnosed with autoimmune hepatitis five years prior and later developed symptoms of systemic lupus erythematosus. The patient was successfully managed with immunosuppressive medication. This research sheds light on the rare entity of AIH subacute cutaneous lupus erythematosus overlap syndrome. [Extracted from the article]

A recent study conducted by researchers at Sao Paulo State University (UNESP) in Brazil explores the risks and benefits of using anti-tumor necrosis factor (TNF) therapy for ulcerative colitis (UC) in a patient with autoimmune hepatitis-related cirrhosis. The study focuses on a rare case of a 28-year-old female patient who had liver cirrhosis due to autoimmune hepatitis (AIH) and UC that was unresponsive to conventional treatment. The patient was treated with infliximab, a TNF inhibitor, and initially showed a positive response. However, after eight months of therapy, the patient developed pneumonia with complications and died. The study highlights the importance of carefully evaluating the best treatment options for patients with overlapping IBD and AIH, considering the potential side effects, particularly infections, especially in patients with cirrhosis. [Extracted from the article]

Researchers from the First Affiliated Hospital of Wenzhou Medical University have conducted a study on experimental autoimmune hepatitis (AIH) and its potential treatment options. The study focused on the role of fibroblast growth factor 4 (FGF4) in regulating M1 macrophages and reducing liver inflammation in AIH. The researchers found that FGF4 treatment activated the PI3K-AKT signaling pathway in macrophages, leading to a reduction in M1 macrophages and hepatic inflammation. This study suggests that FGF4 may be a novel target for treating inflammation in patients with AIH. [Extracted from the article]

A case study conducted by researchers at Manchester University NHS Foundation Trust in the United Kingdom has reported a case of autoimmune hepatitis associated with the use of the PCSK9 inhibitor alirocumab. The study describes the case of a 61-year-old woman who developed hepatitis after being prescribed atorvastatin for familial hypercholesterolemia. After her liver function tests normalized, she was prescribed alirocumab, which also led to hepatitis. A liver biopsy confirmed that she had autoimmune hepatitis with presumed drug injury, making this the first reported case of autoimmune hepatitis associated with alirocumab. [Extracted from the article]

A recent study conducted by researchers at Eskisehir Osmangazi University focused on the relationship between systemic lupus erythematosus (SLE) and hepatic hemangiomas. SLE is an autoimmune disease that affects multiple organs, including the liver. The study reported a case of a 36-year-old woman with SLE who was diagnosed with multiple hepatic hemangiomas. The researchers highlighted the potential increased incidence of hepatic hemangiomas in individuals with SLE. This study provides valuable insights into the connection between SLE and hepatic hemangiomas, shedding light on a topic that has not been extensively studied. [Extracted from the article]

A recent report from Gachon University in South Korea discusses the genetic mutations associated with TNFAIP3 (A20) haploinsufficiency and their impact on inflammatory diseases. The TNFAIP3 gene plays a significant role in immune regulation and the initiation of immune responses. Mutations in this gene have been linked to various immune-related diseases, including Behcet's disease, rheumatoid arthritis, and autoimmune hepatitis. These mutations can lead to a range of symptoms, such as recurrent fever, ulcers, musculoskeletal and gastrointestinal dysfunctions, and cardiovascular issues. While there is currently no definitive treatment for A20 haploinsufficiency, therapeutic strategies can help alleviate symptoms. The study emphasizes the importance of genetic testing for the TNFAIP3 gene in patients with autoinflammatory disorders to guide treatment decisions. [Extracted from the article]

A 61-year-old man developed autoimmune hepatitis (AIH) after receiving the tozinameran COVID-19 vaccine. The man had a history of obesity and other medical conditions, and experienced symptoms such as fatigue and jaundice after receiving the vaccine. Laboratory tests and imaging confirmed the diagnosis of AIH, and the man was treated with prednisone and eventually underwent a liver transplant. The acute liver failure and other complications were attributed to AIH. [Extracted from the article]

This article discusses a newly launched clinical trial, NCT06525909, which aims to study the immune status of patients with Chronic Hepatitis B (CHB) in different clinical stages. The trial intends to establish staging and grading criteria for the immune exhaustion status of CHB patients. The study will include two groups of patients, untreated patients who meet specific criteria and patients who have achieved HBV DNA suppression through treatment. The trial will follow up with patients at regular intervals to collect clinical indicators and specimens for further immune study. [Extracted from the article]

A new report discusses research on intrahepatic cholestasis, a disorder characterized by intermittent episodes of cholestatic jaundice. The report presents a case study of a 13-year-old Pakistani girl with recurrent intrahepatic cholestasis who has a unique homozygous USP53 genetic mutation, the first patient in the South Asian region to present with this mutation. Initially misdiagnosed as autoimmune hepatitis, the patient has since been properly diagnosed and managed with medication, responding well to treatment. This research provides valuable insights into the genetic factors contributing to intrahepatic cholestasis. [Extracted from the article]

A recent study conducted at the University Medical Centre Hamburg-Eppendorf (UKE) in Germany explored the optimization of thiopurine therapy in autoimmune hepatitis (AIH). The researchers investigated whether patients could be stratified based on their response to thiopurine metabolites and examined the effects of azathioprine dosage increases and co-therapy with allopurinol on metabolite profiles and treatment response. The study found that maintaining complete biochemical remission (CBR) in AIH was associated with specific levels of thiopurine metabolites. For patients who did not achieve CBR despite dose increases, the addition of allopurinol alongside low-dose thiopurines was found to be an effective alternative. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Wenzhou Medical University has found that one-third of patients with autoimmune hepatitis (AIH) have cirrhosis at the time of diagnosis. The study aimed to explore the role of polymeric immunoglobulin receptor (pIgR) in regulating the secretion of regenerating islet-derived 3 beta (Reg3b) and the composition of gut microbiota in AIH. The researchers discovered that pIgR facilitates the upregulation of Reg3b through the STAT3 pathway, which plays a crucial role in maintaining the balance of intestinal microbiota in AIH. These findings provide new molecular targets for the diagnosis and treatment of AIH. [Extracted from the article]

A new report from Vilnius University in Lithuania discusses a rare case of bullous morphea associated with autoimmune hepatitis. Bullous morphea is a rare form of localized scleroderma characterized by the presence of sporadic and intermittent blisters on sclerodermatous skin. The exact mechanisms that lead to the development of this condition are largely unknown, making diagnosis and treatment challenging. The case report highlights the importance of considering overlapping autoimmune conditions and the potential efficacy of systemic corticosteroids in managing bullous morphea. Further research is needed to better understand the pathogenesis of this condition and develop more effective treatment options. [Extracted from the article]

A study conducted by the Karolinska Institute in Stockholm, Sweden, examined the long-term outcomes of pediatric primary sclerosing cholangitis (PSC), a rare liver disease associated with inflammatory bowel disease. The study followed 124 children diagnosed with PSC between 2000 and 2015 until 2021. The results showed that children with PSC had a good prognosis during the first decade after diagnosis, with a 91% transplant-free survival rate after 10 years. However, a high SCOPE index at diagnosis was associated with a less favorable outcome. The study provides valuable information for healthcare professionals, individuals, and families affected by PSC. [Extracted from the article]

A case report published in Reactions Weekly describes a woman with autoimmune hepatitis (AIH) who experienced headaches and lack of efficacy with multiple drugs used to treat her condition. The woman had a history of AIH and arthritis and had been receiving treatment with hydroxychloroquine and meloxicam. Despite being treated with azathioprine, corticosteroids, mercaptopurine, mycophenolate mofetil, and tacrolimus, her liver biochemistry did not normalize, indicating lack of efficacy. After discontinuing these drugs and starting sirolimus, she achieved sustained remission of AIH with the addition of prednisone to her treatment regimen. [Extracted from the article]

In a retrospective study involving 18 children with autoimmune hepatitis, two cases were described where the patients did not respond to treatment with steroids, azathioprine, or mycophenolate-mofetil. In both cases, the initial treatment with steroids and azathioprine was ineffective, leading to a switch to mycophenolate-mofetil. However, mycophenolate-mofetil also did not produce a response in one of the cases, and the patient received cyclosporine as an alternative treatment. The study provides insights into the lack of efficacy of these medications in certain cases of autoimmune hepatitis in children. [Extracted from the article]

A study conducted by the Department of Gastroenterology and Hepatology in Roeselare, Belgium, has found that a rare case of drug-induced liver injury was caused by a CYP2D6 gene polymorphism that led to dysfunction and accumulation of a potentially hepatotoxic metabolite of the drug Trazodone. The patient, a 46-year-old female with a history of type I diabetes, alopecia areata, and autoimmune hypothyroidism, experienced significant hepatocellular hepatitis. The researchers recommend targeted pharmacogenomic testing to minimize the risk of drug-induced liver injury. This research has been peer-reviewed and published in Acta Gastro Enterologica Belgica. [Extracted from the article]

A new report from the Indiana University School of Medicine provides insights into the liver manifestation of patients with celiac disease (CD). The study analyzed liver biopsies from 36 patients with CD and found that most cases had an underlying condition, such as autoimmune hepatitis or primary biliary cholangitis. The most common histologic pattern observed was steatosis, with some cases showing severe steatohepatitis. The study suggests that CD injury should be considered in liver biopsies with nonspecific portal and/or lobular inflammation. [Extracted from the article]

A review conducted by researchers at Shiraz University of Medical Sciences in Iran discusses the potential of regulatory T-cell (Treg) infusion therapy in the treatment of autoimmune diseases and organ transplantation. The infusion of Tregs has shown promise in preventing autoimmune reactions and acute/chronic allograft rejection. The review highlights the efficacy of Treg therapy in various autoimmune diseases and allograft transplantation, but also acknowledges the technical challenges and limitations of this approach. The research provides an up-to-date overview of Treg infusion-based treatments and their strengths and limitations. [Extracted from the article]

A case report published in Reactions Weekly describes a 20-year-old man who developed adult-onset Still's disease (AOSD) after receiving a papillomavirus-vaccines vaccination. The man presented with fever, malaise, headaches, dark-colored urine, and vomiting. Initial lab results showed abnormalities in liver function and other markers of inflammation. Despite negative infectious and autoimmune workups, the diagnosis of AOSD following the vaccination was made based on clinical criteria. The patient was treated with prednisone and showed significant improvement. Further follow-up appointments showed continued improvement, and the patient was prescribed anakinra but decided to stop unless another flare-up occurred. [Extracted from the article]

An adult woman with ulcerative pancolitis exhibited lack of efficacy during treatment with infliximab and vedolizumab. She presented to the emergency department with severe abdominal pain, vomiting, and bloody diarrhea. It was determined that she had primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome. She was treated with prednisone, azathioprine, ustekinumab, and off-label vancomycin, which resulted in partial improvement and normalization of her biochemical markers. [Extracted from the article]

A 57-year-old woman with autoimmune hepatitis and liver cirrhosis experienced a lack of efficacy during treatment for disseminated cryptococcosis with amphotericin-b, fluconazole, and flucytosine. Initially, she was treated with antibiotics for presumed bacterial septic arthritis, but her condition worsened and Cryptococcus was identified. Despite aggressive treatment, her clinical condition deteriorated, and she ultimately passed away. The lack of efficacy was attributed to the combination of amphotericin-b, fluconazole, and flucytosine. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the development of autoimmune hepatitis in mice with a deficiency in DNase II. The study found that these mice exhibited features similar to human autoimmune hepatitis, including liver inflammation and fibrosis. The infiltration of various immune cells, such as T cells and monocytes, was observed, and the expression of TLR9 by bone marrow-derived cells was found to be necessary for the development of autoimmune hepatitis. The study also highlighted the role of IFNγ signaling in the recruitment and activation of these immune cells. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at the University of Pennsylvania examined the factors associated with treatment patterns in US patients with autoimmune hepatitis (AIH). The study found that while long-term corticosteroid avoidance is a common goal in managing AIH, prolonged immunosuppression is often necessary to prevent disease progression. The research identified patient and provider factors that influenced treatment choices, such as ethnicity, cirrhosis, osteoporosis, and provider experience. The study also revealed that long-term prednisone therapy is still prevalent, particularly among patients with comorbidities that may be aggravated by corticosteroids. [Extracted from the article]

A new report from Henry Ford Hospital discusses a case of acute onset nitrofurantoin-induced autoimmune hepatitis after treatment for a urinary tract infection (UTI). An 84-year-old woman developed autoimmune hepatitis less than 3 weeks after taking the antibiotic nitrofurantoin. The patient experienced symptoms such as jaundice, abdominal pain, nausea, and vomiting. The study highlights the importance of recognizing drug-induced autoimmune hepatitis, especially in older adults and shortly after common drug exposures for treating UTIs. The patient's liver damage was associated with nitrofurantoin use, and she experienced rapid recovery with prednisone therapy. [Extracted from the article]

A 34-year-old woman with autoimmune hepatitis was admitted to the hospital for a liver transplant. During her admission, she developed dyspnea and was diagnosed with pneumocystis jirovecii pneumonia (PJP). She was treated with cotrimoxazole and prednisone, but unfortunately, she died from respiratory failure caused by PJP. This case report suggests that the combination of cotrimoxazole and prednisone was not effective in treating the PJP infection in this particular patient. [Extracted from the article]

A recent study conducted by researchers at the University of Bologna in Italy has focused on the identification of smooth muscle antibodies (SMA) as highly specific markers for type 1 autoimmune hepatitis (AIH-1). The study compared the diagnostic accuracy of an embryonal aorta vascular smooth muscle (VSM) cell line-based assay with a rodent tissue-based assay for the detection of MF-SMA pattern in AIH-1 patients and controls. The results showed that the VSM cell-based assay had similar specificity but higher sensitivity compared to the rodent tissue-based assay. The study suggests that the VSM cell-based assay could be a reliable method for detecting AIH-specific SMA. [Extracted from the article]

A new study conducted by the All India Institute of Medical Sciences (AIIMS) in Odisha, India, explores the prevalence of acute-on-chronic liver failure (ACLF) in patients with autoimmune hepatitis (AIH). The study analyzed data from six studies involving 985 AIH patients and found that the pooled prevalence of ACLF in these patients was 12%. The study also revealed that two-thirds of patients responded to treatment, but the mortality rate was high at 32%. These findings highlight the global health problem of ACLF and provide valuable insights into its prevalence and treatment outcomes in AIH patients. [Extracted from the article]